Young is an Advisor to LSV. He assists the LSV biopharmaceutical team with deal sourcing, due diligence, and portfolio company management. He initially joined LSV in April 2021 as an Operating Partner.
Young is an accomplished executive with significant operating and venture capital experience.
He is currently the CEO of Alchemab Therapeutics, an LSV portfolio company focused on developing novel antibody therapeutics generated from patients resilient to disease.
Young is also a member of the board of directors of ADMA Biologics, (Nasdaq: ADMA), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics.
Young held a variety of leadership roles over ten years as a senior executive at Momenta Pharmaceuticals, a public biotech company, prior to its sale to Johnson & Johnson for $6.5 billion. Young was most recently Chief Financial and Business Officer at Momenta, where he had responsibility for business development, strategy, finance, investor relations, and commercial. Young led public equity financings raising nearly $500 million, and led the company’s sale to J&J. Prior to Momenta, Young was a business development professional at Biogen, driving a variety of transactions. Young previously worked at Advanced Technology Ventures, working with the team on investments including Acceleron, Five Prime, Hypnion, and Zeltiq.